ERBB2 and biliary tract cancer: In a retrospective analysis, Javle et al. evaluated the application of HER2/neu-directed therapy (trastuzumab, lapatinib, or pertuzumab) in 14 patients with biliary tract cancer, of whom eight persons had a HER2/neu gene amplification or overexpression.